**Introduction:** Gout arthropathy is a common condition. Although acute attacks are treatable with anti-inflammatory medications and attack frequency can be reduced with urate-lowering therapies, a subset of patients are unable to take first line treatments due to co-morbidities, drug reactions or intolerances. In patients with renal impairment, treatment of gout can be particularly challenging. Co-existent infection can also limit treatment options during acute gout flares. Recently, new agents have become available in the treatment of gout. EULAR guidelines (2016) recommend use of interleukin-1 blockers for patients with frequent flares and contra-indications to colchicine, corticosteroids and NSAIDs. For patients with severe refractory gout, recombinant uricases have been shown to be efficacious as urate-lowering agents. We present an interesting case of a gentleman presenting with polyarticular flare of severe gout, as well as septic arthritis of his right knee. He was found to have severe renal impairment. After admission, despite appropriate antibiotic therapy, he deteriorated with sepsis syndrome and oliguric renal failure requiring haemodialysis. Despite resolution of the initial infection, inflammatory markers remained high with ongoing severe gout flare resistant to steroid therapy. He was treated with anti IL-1 Anakinra with improvement of his gout. We then chose to give Rasburicase to control hyperuricaemia with introduction of long term urate lowering therapy with Febuxostat. This case highlights clinical complications which make treating gout challenging. It also highlights situations where new agents IL-1 antagonists and recombinant uricases have a role in gout management.

**Case description:** Our patient (WG) is a 54 year old man presented to A&E on 1/4/17. He had been troubled by bilateral hand and wrist pain as well as severe right knee pain for several days. His joints had not improved with colchicine, his pain had become unbearable, and he became immobile. WG had a past medical history of Type 1 diabetes mellitus, hypertension and obesity. His diabetes had been poorly controlled resulting in diabetic nephropathy (CKD4) and diabetic retinopathy. He had a metallic aortic valve replacement in 2000, and a subsequent aortic root replacement for root aneurysm in 2006. He had one previous ICU admission for pneumonia in 2014. Lastly, he had a long history of recurrent gout attacks. He was seen in 2013 by rheumatology, having had recurrent gout attacks and a serum urate of 670umol/l. He had been treated with Allopurinol, without obtaining control of serum urate and the drug was stopped ss renal impairment progressed. He had been lost to follow up in rheumatology. He was next seen in 2016 with multiple tophi, active synovitis at several joints, and serum urate 680umol/l. He had been taking Colchicine for recurrent attacks with partial relief. He was started on Febuxostat but did not tolerate du to headache and dizziness. On this admission, he had several hot joints, particularly his right knee. He had synovitis at both wrists, several MCP joints on both hands and both knees, with tense effusion on the right. There were abundant large tophi, particularly over both hands. On the dorsum of his left foot and toes there was some chronic ulceration. There was no obvious cellulitis. Chest was clear, abdomen soft, there was a soft systolic murmur with metallic 2nd heart sound and no stigmata of endocarditis. Temperature was 37.2, heart rate 94, and blood pressure 134/88. Bloods on admission revealed CRP 303, WCC 6.0, Urate 579. Urea 44, Creatinine 839, eGFR 6, INR 16, Hb 95. Chest xray was normal, urinalysis negative. The clinical impression was of flare of gout with possible co-existent septic arthritis. He was commenced on broad spectrum antibiotics, initially Flucloxacillin, Benzyl penicillin and Rifampicin, on infectious diseases team advice. In addition, he was treated with oral corticosteroid to treat acute gout flare. He was given vitamin K and his INR quickly normalized. He was therefore commenced on an unfractionated heparin infusion. Right knee was aspirated once INR improved, obtaining extremely cloudy, chalky fluid. Gram stain identified gram positive cocci. Microscopy revealed plentiful urate crystals On day 2 of admission he became more unwell, was febrile (Temperature 38.4C) and hyperglycaemic. There had been no improvement in renal function. Orthopaedics were asked to wash out his knee but it was felt that he was too unwell for a surgical procedure. 3 sets of Blood cultures grew Streptococcus gallolyticus and staphylococcus aureus. Right knee aspirate grew streptococcus gallolyticus. Antibiotics therapy was adjusted. He responded to treatment for sepsis with improvement in haemodynamic parameters and renal function. His joints remained extremely hot, red and sore. Both knees had tense effusions. A second knee aspiration grew Staphylococcus capitis and Streptococcus gallolyticus. Over the next few days culture of 2 subsequent right knee aspirations and one of his left knee were negative. Further blood cultures were also negative. Each of his joint aspirates contained abundant monosodium urate crystals and extremely large numbers of neutrophil polymorphs. Bloods after one week showed Urea 43, Creatinine 365, CRP 225. A week later, with ongoing antibiotics and steroid therapy, CRP 265, Urea 52, Creatinine 611, potassium 6.3, eGFR 8. At this point he became oliguric and was transferred to the renal unit to commence renal replacement therapy. He commenced haemodialysis. Repeated cultures were negative but CRP remained \>200 and his joints did not settle. He was noted to have developed a dusky 2nd toe on left foot since admission. There was visible pus and erythema. The vascular team reviewed and felt there was probable osteomyelitis and ischaemia. He required amputation. Bone specimens grew Escherischia coli. Repeated knee aspiration again showed abundant crystals but no bacteria. He was further investigated for sources of sepsis, with echocardiogram (moderate left ventricular dysfunction, but normal prosthetic valve and no vegetations), and colonoscopy (2 benign polyps seen only). We elected to treat with Anakinra because of a lack of response to prednisolone and/or colchicine, despite concerns about infection and renal failure. His infected toe had been amputated, repeated cultures from blood and right knee showed no further growth, he was on broad spectrum antibiotics, and he was on haemodialysis. Due to renal failure, we elected to commence Anakinra at lower dose (alternate days). Over the next week, joint pain markedly improved. There was some reduction in erythema and swelling and the CRP fell. He was able to transfer out of bed and spend time sitting in a chair. He was dialysed for 1 month, then there was a trial of stopping dialysis. He required high dose intravenous loop diuretics to maintain urine output. After a month off dialysis his renal function gradually deteriorated requiring recommencement of haemodyalysis. Anakinra was stopped after a total of 3 weeks. In addition, his Prednisolone was tapered gradually and stopped. Inflammation markers failed to settle, even with ongoing antibiotics and improvement of his gout. A repeat MRI of left foot showed progressive osteomyelitis involving the 1st 3 metatarsals. His antibiotic regime was again altered. The right knee remained hot and tense, orthopaedics reviewed and didn't feel surgical intervention was warranted. An MRI revealed ongoing effusion but no osteomyelitis. In order to reduce serum uric acid we decided to treat with 5 day course of Rasburicase. Low dose Febuxostat (40mg once dailly) was also re-introduced with the aim of maintaining a low serum urate. His joints improved. There was improvement in size of tophi. Serum urate fell to \< 60umol/l. CRP fell to 57. He has discontinued renal replacement therapy and there has been some recovery in renal function. He continues on longterm antibiotics for treatment of osteomyelitis and he is beginning to work on transfers and mobility.

**Discussion:** This case raised some challenging issues, including: Treatment of severe acute gout with co-existent joint infection. Decisions regarding treatment of ongoing severe gout once initial infection treated. Difficulties in treating acute gout in unwell patients with renal and cardiac co-morbidities. Choices of urate lowering therapies. Limitations of gout treatments for patients on renal replacement therapy. Evidence for use of Rasburicase, in different regimens (ie. Daily for 5 days v monthly for 6 months). Safety and efficacy of febuxostat in CKD4/CKD5/RRT. Role of IL1 Antagonists, particularly in context of RRT/CKD5, and in sepsis We felt that this gentleman\'s severe gout had caused significant pain, rendered him bed bound and there was a massive systemic inflammatory response due to this. Despite his co-existent renal and infection problems, we decided aggressive treatment of gout was warranted. He did not respond to corticosteroids so we decided to use anti-IL1 and then rasburicase. The best situations to use these new agents and in which dosing regimens remains a debatable area. Rasburicase use is limited by infusion reactions. Particularly in renal impairment, there is little evidence to guide treatment.

**Key learning points:** Uncontrolled gout can be a debilitating illness. Acute gout and joint infection can co-exist in same joint. Anakinra is effective in treating acute severe gout but there are cautions and risks, most notably infections. Rasburicase is a potent and fast acting serum urate lowering therapy
